Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity

Background T cell checkpoint immunotherapies have shown promising results in the clinic, but most patients remain non-responsive. CD47-signal regulatory protein alpha (SIRPα) myeloid checkpoint blockade has shown early clinical activity in hematologic malignancies. However, CD47 expression on periph...

Full beskrivning

Bibliografiska uppgifter

Huvudupphov:	Shahram Salek-Ardakani, Wenjing Yang, Sheng Ding, Shih-Hsun Chen, Pawel K Dominik, Jessica Stanfield, Nadia Kurd, Ryan Llewellyn, Jonathan Heyen, Carole Wang, Zea Melton, Thomas Van Blarcom, Kevin C Lindquist, Javier Chaparro-Riggers
Materialtyp:	Artigo
Språk:	Inglês
Utgiven:	BMJ Publishing Group 2021-10-01
Serie:	Journal for ImmunoTherapy of Cancer
Länkar:	https://jitc.bmj.com/content/9/10/e003464.full
Taggar:	Lägg till en tagg Inga taggar, Lägg till första taggen!